These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35076018)

  • 1. Personalized computational heart models with T1-mapped fibrotic remodeling predict sudden death risk in patients with hypertrophic cardiomyopathy.
    O'Hara RP; Binka E; Prakosa A; Zimmerman SL; Cartoski MJ; Abraham MR; Lu DY; Boyle PM; Trayanova NA
    Elife; 2022 Jan; 11():. PubMed ID: 35076018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
    McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
    J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arrhythmia in hypertrophic cardiomyopathy: Risk prediction using contrast enhanced MRI, T1 mapping, and personalized virtual heart technology.
    O'Hara RP; Prakosa A; Binka E; Lacy A; Trayanova NA
    J Electrocardiol; 2022; 74():122-127. PubMed ID: 36183522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.
    Raiker N; Vullaganti S; Collins JD; Allen BD; Choudhury L
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1147-1156. PubMed ID: 32166506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia.
    Dimitrow PP; Klimeczek P; Vliegenthart R; Pasowicz M; Oudkerk M; Podolec P; Tracz W; Dubiel JS
    Int J Cardiovasc Imaging; 2008 Jan; 24(1):77-83; discussion 85-7. PubMed ID: 17624806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
    Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK
    Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features.
    Bongioanni S; Spirito P; Masi AS; Chiribiri A; Bonamini R; Conte MR
    Circ Cardiovasc Imaging; 2009 Jul; 2(4):349-50. PubMed ID: 19808616
    [No Abstract]   [Full Text] [Related]  

  • 14. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias.
    Ariga R; Tunnicliffe EM; Manohar SG; Mahmod M; Raman B; Piechnik SK; Francis JM; Robson MD; Neubauer S; Watkins H
    J Am Coll Cardiol; 2019 May; 73(20):2493-2502. PubMed ID: 31118142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Repolarization Pattern and Left Ventricular Mass in Hypertrophic Cardiomyopathy.
    Azevedo PMO; Guerreiro C; Ladeiras-Lopes R; Ferreira N; Faria R; Barbosa R; Primo J; Braga J
    Cardiology; 2020; 145(5):303-308. PubMed ID: 32018270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between myocardial bridging and fatal ventricular arrhythmias in patients with hypertrophic cardiomyopathy: the HCM-MB study.
    Güner A; Atmaca S; Balaban İ; Türkmen İ; Çeneli D; Türkvatan A; Öner E; Sürgit Ö; Güler A; Uzun F; Babür Güler G; Kahraman S; Pala S; Havan N; Yıldız M; Ertürk M
    Herz; 2023 Oct; 48(5):399-407. PubMed ID: 37081129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis.
    Briasoulis A; Mallikethi-Reddy S; Palla M; Alesh I; Afonso L
    Heart; 2015 Sep; 101(17):1406-11. PubMed ID: 26060120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.